Literature DB >> 2650719

Tumor cell proliferation kinetics and tumor growth rate.

M Tubiana1.   

Abstract

The present knowledge on the growth rate and the proliferation kinetics of human tumor is based on the measurement of the tumor doubling times (DT) in several hundred patients and on the determination of the proportion of proliferating cells with radioactive thymidine or by flow cytometry in large numbers of patients. The results show that the DT of human tumor varies widely, from less than one week to over one year with a median value of approximately 2 months. The DTs are significantly correlated with the histological type. They depend upon 1) the duration of the cell cycle whose mean duration is 2 days with small variations from tumor to tumor, 2) the proportion of proliferating cells and consequently the cell birth rate which varies widely among tumors and which is significantly correlated to the DT, 3) the cell loss factors which also vary widely and which are the greatest when proliferation is most intensive. These studies have several clinical implications: a) they have further increased our understanding of the natural history of human tumor, b) they have therapeutic implications since tumor responsiveness and curability by radiation and drugs are strongly influenced by the cell kinetic parameters of the tumor, c) the proportion of proliferating cells is of great prognostic value in several types of human cancers. The investigation of the molecular defects, which are correlated with the perturbation of control of cell proliferation, should lead to significant fundamental and therapeutic advances.

Entities:  

Mesh:

Year:  1989        PMID: 2650719     DOI: 10.3109/02841868909111193

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  29 in total

Review 1.  Endometriosis-associated ovarian cancer occurs early during follow-up of endometrial cysts.

Authors:  Kosuke Murakami; Yasushi Kotani; Reona Shiro; Hisamitsu Takaya; Hidekatsu Nakai; Noriomi Matsumura
Journal:  Int J Clin Oncol       Date:  2019-08-31       Impact factor: 3.402

2.  The scientific bases of cancer management: at the interface between fundamental research and clinical practice.

Authors:  M Tubiana
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

3.  In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer.

Authors:  Michiko Kodama; Takahiro Kodama; Justin Y Newberg; Hiroyuki Katayama; Makoto Kobayashi; Samir M Hanash; Kosuke Yoshihara; Zhubo Wei; Jean C Tien; Roberto Rangel; Kae Hashimoto; Seiji Mabuchi; Kenjiro Sawada; Tadashi Kimura; Neal G Copeland; Nancy A Jenkins
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-15       Impact factor: 11.205

4.  Immunohistochemical detection of cell growth fraction in formalin-fixed and paraffin-embedded murine tissue.

Authors:  P Birner; M Ritzi; C Musahl; R Knippers; J Gerdes; T Voigtländer; H Budka; J A Hainfellner
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

5.  Increased Serine Synthesis Provides an Advantage for Tumors Arising in Tissues Where Serine Levels Are Limiting.

Authors:  Mark R Sullivan; Katherine R Mattaini; Emily A Dennstedt; Anna A Nguyen; Sharanya Sivanand; Montana F Reilly; Katrina Meeth; Alexander Muir; Alicia M Darnell; Marcus W Bosenberg; Caroline A Lewis; Matthew G Vander Heiden
Journal:  Cell Metab       Date:  2019-03-21       Impact factor: 27.287

6.  Association of Uveal Melanoma Metastatic Rate With Stochastic Mutation Rate and Type of Mutation.

Authors:  Eszter Szalai; Yi Jiang; Natasha M van Poppelen; Martine J Jager; Annelies de Klein; Emine Kilic; Hans E Grossniklaus
Journal:  JAMA Ophthalmol       Date:  2018-10-01       Impact factor: 7.389

Review 7.  Natural history of human breast cancer: recent data and clinical implications.

Authors:  M Tubiana; S Koscielny
Journal:  Breast Cancer Res Treat       Date:  1991-08       Impact factor: 4.872

8.  Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy.

Authors:  Adam C Palmer; Peter K Sorger
Journal:  Cell       Date:  2017-12-14       Impact factor: 41.582

9.  Modelling recurrence and second cancer risks induced by proton therapy.

Authors:  V S K Manem; A Dhawan
Journal:  Math Med Biol       Date:  2018-09-11       Impact factor: 1.854

Review 10.  Why Great Mitotic Inhibitors Make Poor Cancer Drugs.

Authors:  Victoria C Yan; Hannah E Butterfield; Anton H Poral; Matthew J Yan; Kristine L Yang; Cong-Dat Pham; Florian L Muller
Journal:  Trends Cancer       Date:  2020-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.